Intercept Pharmaceuticals, Inc. Loss Submission Form

See If You Qualify For Monetary Reward

Enter your details and we will calculate your loss for you

Submit Transaction Detail Now (Optional)

- OR -

    This submission does not create an attorney-client relationship. We will keep you up to date with this investigation, and should this investigation evolve, we will contact you to discuss whether to establish an attorney client relationship at no cost to you.

    Review Our Privacy Policy

    FAX: 212-363-7171

    Levi & Korsinsky, LLP announces that a ICPT class action lawsuit has been filed on behalf of investors who purchased Intercept Pharmaceuticals, Inc. (ICPT) securities between September 28, 2019 and October 7, 2020. For more on the ICPT Lawsuit please contact us today.

    According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid (“OCA”)), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA’s efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company’s New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

    If you suffered a loss in you have until January 4, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.